Lower GI: Anal cancer definitive chemoradiotherapy
Free question published 05 September 2026
A 62-year-old woman presents with a 4 cm squamous cell carcinoma of the anal canal with one suspicious mesorectal node and no distant metastases. She is keen to preserve sphincter function. Which first-line definitive treatment should be recommended?
- AUpfront abdominoperineal resection
- BConcurrent chemoradiotherapy with cisplatin and 5-fluorouracil, as cisplatin gives a higher complete response rate
- CConcurrent chemoradiotherapy with mitomycin and 5-fluorouracil
- DChemoradiotherapy followed by maintenance cisplatin and 5-fluorouracil
- ERadiotherapy alone without concurrent chemotherapy
Why C is correct
ACT II established that fluorouracil and mitomycin with 50.4 Gy radiotherapy in 28 fractions should remain standard practice in the UK for anal squamous cell carcinoma. Cisplatin was not superior to mitomycin for complete response (90.5% vs 89.6%, p=0.64) and maintenance chemotherapy gave no progression-free survival benefit.
And why the others are not
- AIncorrect. Surgery is reserved for salvage of persistent or recurrent disease; chemoradiotherapy preserves the sphincter as first-line treatment.
- BIncorrect. Cisplatin was not superior to mitomycin for complete response (90.5% vs 89.6%, p=0.64).
- DIncorrect. ACT II showed maintenance chemotherapy gave no improvement in progression-free survival (74% vs 73%, p=0.70).
- EIncorrect. Concurrent chemotherapy improves outcomes over radiotherapy alone and is standard for localised anal cancer.
Source ACT II trial — chemoradiotherapy for squamous-cell carcinoma of the anus — James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013.
More free lower gi questions
- Lower GI: Total neoadjuvant therapy (FOLFIRINOX) · 25 August 2026
- Lower GI: Preoperative versus postoperative chemoradiotherapy · 14 August 2026
- Lower GI: MRI risk stratification for neoadjuvant therapy · 03 August 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing